Drug intelligence / Profile preview

EB02

Development stage: Phase 2
Lead developer: Edesa Biotech
Administration: Topical, Anorectal

Overview

EB02 is a pharmaceutical product developed by Edesa Biotech, licensed from Yissum Research Development Company and Dr. Saul Yedgar. It is a topical formulation of Hyaluronic Acid (HA) conjugated with dipalmitoyl phosphatidyl-ethanolamine (DPPE), also known as MRX-6. EB02 is being developed for the treatment of hemorrhoids and anal fissures, acting as a non-steroidal anti-inflammatory agent. Edesa Biotech holds exclusive worldwide rights for its development, clinical trials, regulatory approval, and commercialization for both human and animal use.

Other names: MRX-6MRX6MRX 6Hyaluronic Acid (HA) conjugated with dipalmitoyl phosphatidyl-ethanolamine (DPPE)

Targets

PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on EB02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB02.

Explore the full profile